Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fiscal Year 2009 (ended March 31, 2009) and Fourth Quarter FY09.
Context: The filing includes unaudited financial results under IFRS and press releases regarding financial performance, regulatory approvals, and a reorganization of drug discovery operations.
Key Financial Metrics
| Metric | FY09 (Rs. Million) | FY09 (USD Million) | FY08 (Rs. Million) | FY08 (USD Million) |
|---|---|---|---|---|
| Revenue | 69,441 | 1,365 | 50,006 | 983 |
| EBITDA | 14,505 | 285 | 9,700 | 190 |
| Gross Profit | 36,500 | 718 | 25,408 | 499 |
| Net Profit (Loss) | (5,168) | (102) | 3,836 | 75 |
| Adjusted PAT | 8,500 | 167 | 4,500 | 88 |
| Diluted EPS | (30.7) | (0.6) | 22.8 | 0.4 |
| Cash & Equivalents | 5,603 | 110 | 7,421 | 146 |
| Total Debt | 19,701 | 387 | 19,352 | 380 |
Note: USD figures are based on a convenience translation rate of 1 USD = Rs 50.87.
Material Changes vs. Prior Period
- Revenue Growth: Overall revenue increased 39% YoY to Rs. 69.4 billion. Excluding the impact of the Sumatriptan launch, organic growth was 24%.
- Profitability Impact: While EBITDA grew 50% to Rs. 14.5 billion, the company reported a Net Loss of Rs. 5.2 billion due to significant non-cash impairment charges.
- Impairment Charges: The German subsidiary (betapharm) recorded a total impairment of Rs. 14,023 million (Rs. 3,167 million for intangibles and Rs. 10,856 million for goodwill) due to a shift to tender-based supply models and decreasing market prices.
- Segment Performance:
- Global Generics: Revenue grew 51% to Rs. 49.8 billion, driven by Sumatriptan and growth in North America and Russia.
- North America: Revenue surged to Rs. 19.8 billion (up from Rs. 8.0 billion), with 58% growth excluding Sumatriptan.
- Russia: Revenue grew 43% to Rs. 5.8 billion.
- PSAI: Revenue increased 13% to Rs. 18.8 billion.
- Operating Expenses: SG&A expenses increased 25% in absolute terms but decreased as a percentage of sales from 34% to 30%.
Outlook, Management Commentary, and Risks
- Management Commentary: Management highlighted that adjusted PAT grew 89% to Rs. 8.5 billion, reflecting strong operational performance despite the one-time impairment. The Board recommended a final dividend of Rs. 6.25 per share.
- Operational Reorganization: Effective July 1, 2009, Drug Discovery operations in Hyderabad will be absorbed into Aurigene (a wholly-owned subsidiary). The Atlanta Research facility in the US will be closed. A new Proprietary Products Group will be formed to manage the R&D portfolio.
- R&D Progress: Three Investigational New Drug (IND) applications were approved. Phase I studies for DRL 17822 (CETP inhibitor for dyslipidemia) have begun. Two other molecules for COPD and Dyslipidemia are also in development.
- Risks and Contingencies:
- Legal: The company incurred Rs. 921 million in damages due to a German court upholding the validity of the olanzapine patent.
- Market: Continued price pressure in the German market due to tender-based supply models.
- Forward-Looking Statements: Risks include changes in global economic conditions, market acceptance of products, and regulatory hurdles.
Key Facts for Investor Verification
- Impairment Validity: Verify the recoverable value assumptions used for the Rs. 14 billion impairment charge at the betapharm subsidiary.
- Sumatriptan Sustainability: Assess the long-term revenue contribution of the Sumatriptan launch, which drove a significant portion of FY09 growth.
- Adjusted Metrics: Confirm the calculation of "Adjusted PAT" and "Adjusted EPS" to understand the core earnings power excluding one-time charges.
- Dividend Approval: Monitor shareholder approval of the recommended final dividend of Rs. 6.25 per share at the Annual General Meeting.
- R&D Pipeline: Track the progress of the three approved INDs and the integration of the Aurigene discovery platform.